Such intra-stage heterogeneity emphasizes the complexity of CRC progression and may be driven by mutations in key driver genes such as APC, KRAS, BRAF, PIK3CA, or TP53, each known to profoundly influence tumor biology and progression patterns. Here, KRAS is linked to neoplasm.